BCAB BIOATLA INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIOATLA INC reported revenue of n/a, net income of $452K and diluted EPS of $0.27; for the fiscal year ended December 2025 revenue was n/a.
BCAB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$59.3M, net income −$59.6M (margin n/a), EPS −$50.66
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$73.9M, net income −$69.8M (margin n/a), EPS −$71.83
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$130M, net income $124M (margin n/a), EPS −$2.58
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$108M, net income −$106M (margin n/a), EPS −$2.74
- Fiscal year ended Dec 2021: revenue $300K, gross profit n/a, operating income −$96.4M, net income −$95.4M (margin -31800.7%), EPS −$2.76
BCAB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $452K, EPS $0.27
- Quarter ended Mar 31, 2026: revenue n/a, net income −$6.34M, EPS −$4.22
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$9.78M, EPS −$21.24
- Quarter ended Sep 30, 2025: revenue n/a, net income −$15.8M, EPS −$0.27
- Quarter ended Jun 30, 2025: revenue n/a, net income −$18.7M, EPS −$15.99
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.3M, EPS −$13.16
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$14.9M, EPS −$70.69
- Quarter ended Sep 30, 2024: revenue n/a, net income −$10.6M, EPS −$0.22
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.1M, EPS −$0.44
- Quarter ended Mar 31, 2024: revenue n/a, net income −$23.2M, EPS −$0.48
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $220M, EPS −$0.55
- Quarter ended Sep 30, 2023: revenue $0, net income −$33.3M, EPS −$0.70
- Quarter ended Jun 30, 2023: revenue $0, net income −$35.8M, EPS −$0.75
- Quarter ended Mar 31, 2023: revenue $0, net income −$27.5M, EPS −$0.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$27.5M, EPS −$0.63
- Quarter ended Sep 30, 2022: revenue $0, net income −$25.8M, EPS −$0.69
- Quarter ended Jun 30, 2022: revenue $0 (down 100.0% year over year), net income −$28.9M, EPS −$0.77
- Quarter ended Mar 31, 2022: revenue $0, net income −$24.3M, EPS −$0.65
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$23.4M, EPS −$0.62
- Quarter ended Sep 30, 2021: revenue n/a, net income −$22.9M, EPS −$0.68
BCAB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$48.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$71.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$104M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$90.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$62.2M, share buybacks n/a
BCAB balance sheet
- Jun 30, 2026: cash $1.54M, total assets $9.51M, total liabilities $45.7M, shareholders' equity −$36.2M
- Mar 31, 2026: cash $1.96M, total assets $8.57M, total liabilities $45.9M, shareholders' equity −$37.3M
- Dec 31, 2025: cash $7.12M, total assets $13.8M, total liabilities $50.0M, shareholders' equity −$36.2M
- Sep 30, 2025: cash $8.32M, total assets $15.9M, total liabilities $47.1M, shareholders' equity −$31.2M
- Jun 30, 2025: cash $18.2M, total assets $27.1M, total liabilities $43.9M, shareholders' equity −$16.7M
- Mar 31, 2025: cash $32.4M, total assets $38.3M, total liabilities $37.7M, shareholders' equity $547K
- Dec 31, 2024: cash $49.0M, total assets $52.4M, total liabilities $38.2M, shareholders' equity $14.3M
- Sep 30, 2024: cash $56.5M, total assets $62.2M, total liabilities $39.3M, shareholders' equity $23.0M
Is BCAB profitable?
No. BIOATLA INC lost $31.5M over the last four quarters.
What is BCAB's EPS?
Diluted earnings per share over the last four quarters were −$25.46; $0.27 in the latest quarter.